Published within
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Although many newer pharmacovigilance solutions are still in the nascent stages, and despite pharmaceutical companies' reluctance to adopt them, it is becoming increasingly obvious that these tools will play an essential role in protecting public health. As drug safety regulations increase, signal detection technologies will aid in the costly act of identifying and managing adverse drug events.
Published By Datamonitor
|
06 Jun 2008 |
|
Expert View
|
With the cost of healthcare provision spiraling, governments and payers across the seven major markets are applying cost-cutting measures, putting even greater pressure on pharmaceutical companies. In the UK, the National Institute of Clinical Excellence recently rejected four new kidney cancer therapies on the basis of cost effectiveness, effectively denying patients access to these novel drugs.
Published By Datamonitor
|
04 Sep 2008 |
|
Expert View
|
One of Barack Obama's key goals as president is to reduce healthcare costs, particularly those related to prescription medications, by increasing the importation of generic drugs. However, the majority of these, or their ingredients, are manufactured in China, and to build confidence in such products, which are often considered unsafe, the FDA will require updated IT systems and solutions.
Published By Datamonitor
|
17 Nov 2008 |
|
Expert View
|
The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.
Published By Datamonitor
|
08 May 2009 |
|
Expert View
|
The evolving relationship between branded and generics pharmaceutical companies is set to undergo considerable change as regulators in both the US and EU move to restrict 'pay-for-delay' deals in a bid to increase generics cost-savings. As deals that delay the market entry of generics come under increasing scrutiny, the industry may find that its best option is to cease such practices altogether.
Published By Datamonitor
|
13 Jan 2010 |
|
CommentWire
|
News of AstraZeneca's Phase III clinical trial program signifies the company's serious intent to enter the rheumatoid arthritis market with its small molecule Syk inhibitor, fostamatinib disodium. While there is an unmet need for oral small molecules, Datamonitor expects that the drug will face stiff competition from Pfizer's tasocitinib, the most advanced novel small molecule in the pipeline.
Published By Datamonitor
|
30 Sep 2010 |
|
CommentWire
|
AusBiotech 2010, the annual conference of the Australian biotechnology industry, has sought to educate attendees about recent trends in the global pharmaceutical market, and how they can best take advantage of current conditions. This includes exploring opportunities with regional Asia Pacific neighbors, with a potential collaboration between Australia and India one of the key talking points.
Published By Datamonitor
|
25 Oct 2010 |
|
CommentWire
|
The European Medicines Agency's latest draft guidelines on monoclonal antibodies offer some flexibility for producers, but development costs are still expected to be high. With the instructions likely to be interpreted on a case-by-case basis, communication with the agency will be critical for success.
Published By Datamonitor
|
30 Nov 2010 |
|
CommentWire
|
The FDA has issued a Complete Response Letter informing Orexigen that its developmental obesity therapy Contrave will require additional clinical study if it is to reach the market. The financial burden of an outcomes study and uncertainties regarding the drug's effect on blood pressure is likely to prevent Contrave from entering the market.
Published By Datamonitor
|
02 Feb 2011 |
|
CommentWire
|
George Osborne, the UK chancellor of the exchequer, has attempted to appease branded pharmaceutical manufacturers in his 2011 budget announcement by introducing lower corporate tax rates and increasing R&D incentives. However, it is still unclear as to whether he will go even further and reform the Bolar exemption, which could harm generic drug producers, and lead to a rise in NHS drug spending.
Published By Datamonitor
|
25 Mar 2011 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.